Drug Profile


Alternative Names: CpG 7909; CPG ODN 2006; CpG oligodeoxynucleotide 7909; PF-3512676; PF-676; ProMune

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Coley Pharmaceutical Group
  • Developer Ohio State University Comprehensive Cancer Center; Pfizer; Stanford University
  • Class Adjuvants; Antineoplastics; Oligodeoxyribonucleotides
  • Mechanism of Action Immunostimulants; Toll-like receptor 9 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Breast cancer
  • Discontinued Basal cell cancer; Non-Hodgkin's lymphoma; Non-small cell lung cancer

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 27 Sep 2010 Discontinued - Phase-II for Non-small cell lung cancer in USA (SC)
  • 24 Jun 2010 Agatolimod is still in phase II trials for Non-small cell lung cancer in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top